Ads
related to: prostate cancer treatment options- nmCRPC Treatment Option
31% Risk of Death Decrease
Visit The Patient Site.
- Dosing & Administration
View Recommended Dosage & Learn
About Drug Interactions Here.
- Clinical Information
Read About A Double-Blind, Placebo-
Controlled, Randomized Study.
- mHSPC Treatment Option
32% Risk of Death Decrease
Visit The Patient Site.
- Patient Profiles
Explore Patient Profiles To Assess
A Treatment Option.
- Downloadable Resources
Resources For Physicians & Patients
Available On The Site To Download.
- nmCRPC Treatment Option
Search results
SARCOMA CLINICAL TRIAL FUNDED BY STAND UP TO CANCER REDUCES RISK OF RELAPSE BY 43%
Tehachapi News· 3 days agoFor the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a ...
Sarcoma immunotherapy clinical trial reduces risk of relapse by 43%
Medical Xpress· 2 days agoFor the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare ...
Hospice (PDQ®)
National Cancer Institute· 2 days agoHealth care professionals and health care systems face many challenges when caring for patients at the end of life (EOL). While hospice is designed specifically for EOL care, patients may decline ...
Breakthrough bowel cancer drug 'could triple survival chances' for patients
Daily Express· 4 days agoA blockbuster drug could triple survival chances for some bowel cancer patients by “melting away”...
Questions About Melanoma? Harvard Health Publishing Has Answers.
MSN News· 4 days agoWhat are the early stages of melanoma? Answered by Dr. Howard E. Lewine M.D. Chief Medical Editor,...
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1...
Morningstar· 5 days agoNuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO ...
Clinical trial leads to FDA approved treatment for peripheral artery disease
MinnPost· 2 days agoPeripheral artery disease or PAD, said Jennifer Jones-McMeans, Ph.D., divisional vice president of...
Breast cancer drug denied on NHS gives incurable women 'precious extra time'
Daily Express· 3 days agoA wonder drug denied to thousands of women in England with incurable breast cancer could keep their...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 days agoFor the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a ...
...Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100%...
Morningstar· 3 days agoCARDIFF, UK / ACCESSWIRE / June 3, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) just announced promising phase 2 results for its newly in-licensed drug eRapa for treating familial adenomatous ...
Ad
related to: prostate cancer treatment options